Gene Therapy Market Size, Share & Trend Analysis Report By Indication (Acute Lymphoblastic Leukemia, Large B-cell Lymphoma), By Vector Type (Lentivirus), By Route of Administration, By Region, And Segment Forecasts, 2024 - 2030

Table of Contents

Chapter 1. Gene Therapy Market: Methodology and Scope
                   1.1. Market Segmentation & Scope
                   1.2. Market Definitions
                       1.2.1. Information Analysis
                       1.2.2. Market Application & Data Visualization
                       1.2.3. Data Validation & Publishing
                   1.3. Research Assumptions
                   1.4. Information Procurement
                       1.4.1. Primary Research
                   1.5. Information or Data Analysis
                   1.6. Market Application & Validation
                   1.7. Market Model
                   1.8. Global Market: CAGR Calculation
                   1.9. Objectives
                       1.9.1. Objective 1
                       1.9.2. Objective 2
Chapter 2. Gene Therapy Market: Executive Summary
                   2.1. Market Snapshot
                   2.2. Segment Snapshot
                   2.3. Competitive Landscape Snapshot
Chapter 3. Gene Therapy Market: Variables, Trends, & Scope
                   3.1. Market Lineage Outlook
                       3.1.1. Parent Market Outlook
                       3.1.2. Related/Ancillary Market Outlook
                   3.2. Market Dynamics
                       3.2.1. Market Driver Analysis
                           3.2.1.1. Robust Gene Therapy Pipeline
                           3.2.1.2. Introduction Of Technological Advancements
                           3.2.1.3. Increasing Investment From Companies And Partnerships
                           3.2.1.4. Growing Prevalence Of Target Diseases And Increased Demand For Innovative Medicine
                       3.2.2. Market Restraint Analysis
                           3.2.2.1. Absence Of Effective Diagnosis Framework
                           3.2.2.2. High Prices Of Gene Therapy
                       3.2.3. Market Opportunity Analysis
                           3.2.3.1. Rising Investment For Adoptive T-Cell Transfer Approaches Of Disease Treatment
                           3.2.3.2. Facility Expansion For Cell And Gene Therapies
                           3.2.3.3. Technological Advancements In Manufacturing Vectors
                   3.3. Industry Analysis Tools
                       3.3.1. Porter’s Five Forces Analysis
                       3.3.2. PESTEL Analysis
                       3.3.3. COVID-19 Impact Analysis
                   3.4. Pipeline Analysis
                       3.4.1. Key takeaways from 2023
                       3.4.2. Gene therapy pipeline: most common targets
                   3.5. Payment & Pricing Models
                       3.5.1. Payment models for innovative therapies
Chapter 4. Route of Administration Business Analysis
                   4.1. Gene Therapy Market: Route of Administration Movement Analysis
                   4.2. Intravenous
                       4.2.1. Intravenous Market, 2018 - 2030 (USD Million)
                   4.3. Others
                       4.3.1. Others Market, 2018 - 2030 (USD Million)
Chapter 5. Indication Business Analysis
                   5.1. Gene Therapy Market: Indication Movement Analysis
                   5.2. Acute Lymphoblastic Leukemia
                       5.2.1. Acute Lymphoblastic Leukemia Market, 2018 - 2030 (USD Million)
                   5.3. Inherited Retinal Disease
                       5.3.1. Inherited Retinal Disease Market, 2018 - 2030 (USD Million)
                   5.4. Large B-Cell Lymphoma
                       5.4.1. Large B-Cell Lymphoma Market, 2018 - 2030 (USD Million)
                   5.5. Adenosine Deaminase (Ada)‐Deficient Severe Combined Immunodeficiency (Scid)
                       5.5.1. Adenosine Deaminase (Ada)‐Deficient Severe Combined Immunodeficiency (Scid) Market, 2018 - 2030 (USD Million)
                   5.6. Melanoma (lesions)
                       5.6.1. Melanoma (lesions) Market, 2018 - 2030 (USD Million)
                   5.7. Beta-Thalassemia Major/Sickle Cell Disease (Scd)
                       5.7.1. Beta-Thalassemia Major/Sickle Cell Disease (Scd) Market, 2018 - 2030 (USD Million)
                   5.8. Head & Neck Squamous Cell Carcinoma
                       5.8.1. Head & Neck Squamous Cell Carcinoma Market, 2018 - 2030 (USD Million)
                   5.9. Peripheral arterial disease
                       5.9.1. Peripheral arterial disease Market, 2018 - 2030 (USD Million)
                   5.10. Spinal Muscular Atrophy (SMA)
                       5.10.1. Spinal Muscular Atrophy (SMA) Market, 2018 - 2030 (USD Million)
                   5.11. Others
                       5.11.1. Others Market, 2018 - 2030 (USD Million)
Chapter 6. Vector Type Business Analysis
                   6.1. Gene Therapy Market: Vector Type Movement Analysis
                   6.2. Lentiviral Vectors
                       6.2.1. Lentiviral Vectors market, 2018 - 2030 (USD Million)
                   6.3. Adeno-Associated Viral (Aav) Vectors
                       6.3.1. Adeno-Associated Viral (Aav) Vectors market, 2018 - 2030 (USD Million)
                   6.4. Retrovirus Vectors
                       6.4.1. Retrovirus Vectors market, 2018 - 2030 (USD Million)
                   6.5. Modified Herpes Simplex Virus
                       6.5.1. Modified Herpes Simplex Virus market, 2018 - 2030 (USD Million)
                   6.6. Adenovirus Vectors
                       6.6.1. Adenovirus Vectors market, 2018 - 2030 (USD Million)
                   6.7. Non-Viral Plasmid Vector
                       6.7.1. Non-Viral Plasmid Vector market, 2018 - 2030 (USD Million)
                   6.8. Others
                       6.8.1. Others market, 2018 - 2030 (USD Million)
Chapter 7. Regional Business Analysis
                   7.1. Gene Therapy Market Share By Region, 2023 & 2030
                   7.2. North America
                       7.2.1. North America Gene Therapy Market, 2018 - 2030 (USD Million)
                       7.2.2. U.S.
                           7.2.2.1. Key Country Dynamics
                           7.2.2.2. Target disease prevalence
                           7.2.2.3. Competitive Scenario
                           7.2.2.4. Regulatory Framework
                           7.2.2.5. U.S. Gene Therapy Market, 2018 - 2030 (USD Million)
                       7.2.3. Canada
                           7.2.3.1. Key Country Dynamics
                           7.2.3.2. Target disease prevalence
                           7.2.3.3. Competitive Scenario
                           7.2.3.4. Regulatory Framework
                           7.2.3.5. Canada Gene Therapy Market, 2018 - 2030 (USD Million)
                   7.3. Europe
                       7.3.1. Europe Gene Therapy Market, 2018 - 2030 (USD Million)
                       7.3.2. UK
                           7.3.2.1. Key Country Dynamics
                           7.3.2.2. Target disease prevalence
                           7.3.2.3. Competitive Scenario
                           7.3.2.4. Regulatory Framework
                           7.3.2.5. UK Gene Therapy Market, 2018 - 2030 (USD Million)
                       7.3.3. Germany
                           7.3.3.1. Key Country Dynamics
                           7.3.3.2. Target disease prevalence
                           7.3.3.3. Competitive Scenario
                           7.3.3.4. Regulatory Framework
                           7.3.3.5. Germany Gene Therapy Market, 2018 - 2030 (USD Million)
                       7.3.4. France
                           7.3.4.1. Key Country Dynamics
                           7.3.4.2. Target disease prevalence
                           7.3.4.3. Competitive Scenario
                           7.3.4.4. Regulatory Framework
                           7.3.4.5. France Gene Therapy Market, 2018 - 2030 (USD Million)
                       7.3.5. Italy
                           7.3.5.1. Key Country Dynamics
                           7.3.5.2. Target disease prevalence
                           7.3.5.3. Competitive Scenario
                           7.3.5.4. Regulatory Framework
                           7.3.5.5. Italy Gene Therapy Market, 2018 - 2030 (USD Million)
                       7.3.6. Spain
                           7.3.6.1. Key Country Dynamics
                           7.3.6.2. Target disease prevalence
                           7.3.6.3. Competitive Scenario
                           7.3.6.4. Regulatory Framework
                           7.3.6.5. Spain Gene Therapy Market, 2018 - 2030 (USD Million)
                   7.4. Asia Pacific
                       7.4.1. Asia Pacific Gene Therapy Market, 2018 - 2030 (USD Million)
                       7.4.2. Japan
                           7.4.2.1. Key Country Dynamics
                           7.4.2.2. Target disease prevalence
                           7.4.2.3. Competitive Scenario
                           7.4.2.4. Regulatory Framework
                           7.4.2.5. Japan Gene Therapy Market, 2018 - 2030 (USD Million)
                       7.4.3. China
                           7.4.3.1. Key Country Dynamics
                           7.4.3.2. Target disease prevalence
                           7.4.3.3. Competitive Scenario
                           7.4.3.4. Regulatory Framework
                           7.4.3.5. China Gene Therapy Market, 2018 - 2030 (USD Million)
                       7.4.4. Australia
                           7.4.4.1. Key Country Dynamics
                           7.4.4.2. Target disease prevalence
                           7.4.4.3. Competitive Scenario
                           7.4.4.4. Regulatory Framework
                           7.4.4.5. Australia Gene Therapy Market, 2018 - 2030 (USD Million)
                   7.5. Rest of the world
                       7.5.1. Rest of the world Gene Therapy Market, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
                   8.1. Company Categorization
                   8.2. Strategy Mapping
                   8.3. Company Market Position Analysis, 2023
                   8.4. Company Profiles
                       8.4.1. REGENXBIO, INC
                           8.4.1.1. Overview
                           8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           8.4.1.3. Product Benchmarking
                           8.4.1.4. Strategic Initiatives
                       8.4.2. OXFORD BIOMEDICA PLC
                           8.4.2.1. Overview
                           8.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           8.4.2.3. Product Benchmarking
                           8.4.2.4. Strategic Initiatives
                       8.4.3. VOYAGER THERAPEUTICS
                           8.4.3.1. Overview
                           8.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           8.4.3.3. Product Benchmarking
                           8.4.3.4. Strategic Initiatives
                       8.4.4. HUMAN STEM CELLS INSTITUTE
                           8.4.4.1. Overview
                           8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           8.4.4.3. Product Benchmarking
                           8.4.4.4. Strategic Initiatives
                       8.4.5. DIMENSION THERAPEUTICS, INC
                           8.4.5.1. Overview
                           8.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           8.4.5.3. Product Benchmarking
                           8.4.5.4. Strategic Initiatives
                       8.4.6. BRISTOL-MYERS SQUIBB COMPANY
                           8.4.6.1. Overview
                           8.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           8.4.6.3. Product Benchmarking
                           8.4.6.4. Strategic Initiatives
                       8.4.7. SANOFI
                           8.4.7.1. Overview
                           8.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           8.4.7.3. Product Benchmarking
                           8.4.7.4. Strategic Initiatives
                       8.4.8. APPLIED GENETIC TECHNOLOGIES CORPORATION
                           8.4.8.1. Overview
                           8.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           8.4.8.3. Product Benchmarking
                           8.4.8.4. Strategic Initiatives
                       8.4.9. F. HOFFMANN-LA ROCHE LTD
                           8.4.9.1. Overview
                           8.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           8.4.9.3. Product Benchmarking
                           8.4.9.4. Strategic Initiatives
                       8.4.10. BLUEBIRD BIO, INC
                           8.4.10.1. Overview
                           8.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           8.4.10.3. Product Benchmarking
                           8.4.10.4. Strategic Initiatives
                       8.4.11. NOVARTIS AG
                           8.4.11.1. Overview
                           8.4.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           8.4.11.3. Product Benchmarking
                           8.4.11.4. Strategic Initiatives
                       8.4.12. TAXUS CARDIUM PHARMACEUTICALS GROUP, INC. (GENE BIOTHERAPEUTICS)
                           8.4.12.1. Overview
                           8.4.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           8.4.12.3. Product Benchmarking
                           8.4.12.4. Strategic Initiatives
                       8.4.13. UNIQURE N.V.
                           8.4.13.1. Overview
                           8.4.13.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           8.4.13.3. Product Benchmarking
                           8.4.13.4. Strategic Initiatives
                       8.4.14. TAKEDA PHARMACEUTICAL COMPANY LIMITED
                           8.4.14.1. Overview
                           8.4.14.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           8.4.14.3. Product Benchmarking
                           8.4.14.4. Strategic Initiatives
                       8.4.15. CELLECTIS S.A.
                           8.4.15.1. Overview
                           8.4.15.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           8.4.15.3. Product Benchmarking
                           8.4.15.4. Strategic Initiatives
                       8.4.16. SANGAMO THERAPEUTICS, INC.
                           8.4.16.1. Overview
                           8.4.16.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           8.4.16.3. Product Benchmarking
                           8.4.16.4. Strategic Initiatives
                       8.4.17. ORCHARD THERAPEUTICS
                           8.4.17.1. Overview
                           8.4.17.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           8.4.17.3. Product Benchmarking
                           8.4.17.4. Strategic Initiatives
                       8.4.18. GILEAD LIFESCIENCES, INC.
                           8.4.18.1. Overview
                           8.4.18.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           8.4.18.3. Product Benchmarking
                           8.4.18.4. Strategic Initiatives
                       8.4.19. BENITEC BIOPHARMA
                           8.4.19.1. Overview
                           8.4.19.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           8.4.19.3. Product Benchmarking
                           8.4.19.4. Strategic Initiatives
                       8.4.20. SIBIONO GENETECH CO., LTD
                           8.4.20.1. Overview
                           8.4.20.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           8.4.20.3. Product Benchmarking
                           8.4.20.4. Strategic Initiatives
                       8.4.21. SHANGHAI SUNWAY BIOTECH CO., LTD.
                           8.4.21.1. Overview
                           8.4.21.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           8.4.21.3. Product Benchmarking
                           8.4.21.4. Strategic Initiatives
                       8.4.22. GENSIGHT BIOLOGICS S.A.
                           8.4.22.1. Overview
                           8.4.22.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           8.4.22.3. Product Benchmarking
                           8.4.22.4. Strategic Initiatives
                       8.4.23. TRANSGENE
                           8.4.23.1. Overview
                           8.4.23.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           8.4.23.3. Product Benchmarking
                           8.4.23.4. Strategic Initiatives
                       8.4.24. CALIMMUNE, INC
                           8.4.24.1. Overview
                           8.4.24.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           8.4.24.3. Product Benchmarking
                           8.4.24.4. Strategic Initiatives
                       8.4.25. EPEIUS BIOTECHNOLOGIES CORP.
                           8.4.25.1. Overview
                           8.4.25.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           8.4.25.3. Product Benchmarking
                           8.4.25.4. Strategic Initiatives
                       8.4.26. ASTELLAS PHARMA INC
                           8.4.26.1. Overview
                           8.4.26.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           8.4.26.3. Product Benchmarking
                           8.4.26.4. Strategic Initiatives
                       8.4.27. AMERICAN GENE TECHNOLOGIES
                           8.4.27.1. Overview
                           8.4.27.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           8.4.27.3. Product Benchmarking
                           8.4.27.4. Strategic Initiatives
                       8.4.28. BIOMARIN PHARMACEUTICALS, INC
                           8.4.28.1. Overview
                           8.4.28.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           8.4.28.3. Product Benchmarking
                           8.4.28.4. Strategic Initiatives

List of Tables

Table 1 List of Secondary Sources
Table 2 List of Tables
Table 3 List of Secondary Sources
Table 4 List of Abbreviations
Table 5 Global Gene Therapy Market by Route Of Administration, 2018 - 2030 (USD Million)
Table 6 Global Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
Table 7 Global Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 8 Global Gene Therapy Market by Region, 2018 - 2030 (USD Million)
Table 9 North America Gene Therapy Market by Route Of Administration, 2018 - 2030 (USD Million)
Table 10 North America Gene Therapy Market by Country, 2018 - 2030 (USD Million)
Table 11 North America Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
Table 12 North America Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 13 U.S. Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
Table 14 U.S. Gene Therapy Market by Route Of Administration, 2018 - 2030 (USD Million)
Table 15 U.S. Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 16 Canada Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
Table 17 Canada Gene Therapy Market by Route Of Administration, 2018 - 2030 (USD Million)
Table 18 Canada Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 19 Europe Gene Therapy Market by Country, 2018 - 2030 (USD Million)
Table 20 Europe Gene Therapy Market by Route Of Administration, 2018 - 2030 (USD Million)
Table 21 Europe Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
Table 22 Europe Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 23 Germany Gene Therapy Market by Route Of Administration, 2018 - 2030 (USD Million)
Table 24 Germany Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
Table 25 Germany Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 26 UK Gene Therapy Market by Route Of Administration, 2018 - 2030 (USD Million)
Table 27 UK Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
Table 28 UK Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 29 France Gene Therapy Market by Route Of Administration, 2018 - 2030 (USD Million)
Table 30 France Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
Table 31 France Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 32 Italy Gene Therapy Market by Route Of Administration, 2018 - 2030 (USD Million)
Table 33 Italy Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
Table 34 Italy Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 35 Spain Gene Therapy Market by Route Of Administration, 2018 - 2030 (USD Million)
Table 36 Spain Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
Table 37 Spain Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 38 Asia Pacific Gene Therapy Market by Route Of Administration, 2018 - 2030 (USD Million)
Table 39 Asia Pacific Gene Therapy Market by Country, 2018 - 2030 (USD Million)
Table 40 Asia Pacific Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
Table 41 Asia Pacific Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 42 China Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
Table 43 China Gene Therapy Market by Route Of Administration, 2018 - 2030 (USD Million)
Table 44 China Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 45 Japan Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
Table 46 Japan Gene Therapy Market by Route Of Administration, 2018 - 2030 (USD Million)
Table 47 Japan Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 48 South Korea Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
Table 49 South Korea Gene Therapy Market by Route Of Administration, 2018 - 2030 (USD Million)
Table 50 South Korea Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 51 Australia Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
Table 52 Australia Gene Therapy Market by Route Of Administration, 2018 - 2030 (USD Million)
Table 53 Australia Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 54 RoW Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
Table 55 RoW Gene Therapy Market by Route Of Administration, 2018 - 2030 (USD Million)
Table 56 RoW Gene Therapy Market by Indication, 2018 - 2030 (USD Million)

List of Figures

Fig. 1 Information Procurement
Fig. 2 Primary Research Pattern
Fig. 3 Market Research Approaches
Fig. 4 Value Chain-Based Sizing & Forecasting
Fig. 5 Market Formulation & Validation
Fig. 6 Gene Therapy Market Segmentation
Fig. 7 Market Driver Relevance Analysis (Current & Future Impact)
Fig. 8 Market Restraint Relevance Analysis (Current & Future Impact)
Fig. 9 Market Challenge Relevance Analysis (Current & Future Impact)
Fig. 10 Penetration & Growth Prospect Mapping
Fig. 11 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
Fig. 12 Porter’s Five Forces Analysis
Fig. 13 Regional Marketplace: Key Takeaways
Fig. 14 Global Gene Therapy Market for Lentivirus, 2018 - 2030 (USD Million)
Fig. 15 Global Gene Therapy Market for AAV, 2018 - 2030 (USD Million)
Fig. 16 Global Gene Therapy Market for RetroVirus & gamma RetroVirus, 2018 - 2030 (USD Million)
Fig. 17 Global Gene Therapy Market for Modified Herpes Simplex Virus, 2018 - 2030 (USD Million)
Fig. 18 Global Gene Therapy Market for Adenovirus, 2018 - 2030 (USD Million)
Fig. 19 Global Gene Therapy Market for Non-viral Plasmid Vector, 2018 - 2030 (USD Million)
Fig. 20 Global Gene Therapy Market for Other Vector Type, 2018 - 2030 (USD Million)
Fig. 21 Global Gene Therapy Market for Acute Lymphoblastic Leukemia (ALL), 2018 - 2030 (USD Million)
Fig. 22 Global Acute Lymphoblastic Leukemia (ALL) patients treated with gene therapy, 2018 - 2030
Fig. 23 Global Gene Therapy Market for Inherited Retinal Disease, 2018 - 2030 (USD Million)
Fig. 24 Global Inherited Retinal Disease patients treated with gene therapy, 2018 - 2030
Fig. 25 Global Gene Therapy Market for Large B-cell Lymphoma, 2018 - 2030 (USD Million)
Fig. 26 Global Large B-cell Lymphoma patients treated with gene therapy, 2018 - 2030
Fig. 27 Global Gene Therapy Market for ADA-SCID, 2018 - 2030 (USD Million)
Fig. 28 Global ADA-SCID patients treated with gene therapy, 2018 - 2030
Fig. 29 Global Gene Therapy Market for Melanoma (lesions), 2018 - 2030 (USD Million)
Fig. 30 Global Melanoma (lesions) patients treated with gene therapy, 2018 - 2030
Fig. 31 Global Gene Therapy Market for Beta-Thalassemia Major/SCD, 2018 - 2030 (USD Million)
Fig. 32 Global Beta-Thalassemia Major/SCD patients treated with gene therapy, 2018 - 2030
Fig. 33 Global Gene Therapy Market for Head & Neck Squamous Cell Carcinoma, 2018 - 2030 (USD Million)
Fig. 34 Global Head & Neck Squamous Cell Carcinoma patients treated with gene therapy, 2018 - 2030
Fig. 35 Global Gene Therapy Market for Peripheral arterial disease, 2018 - 2030 (USD Million)
Fig. 36 Global Peripheral arterial disease patients treated with gene therapy, 2018 - 2030
Fig. 37 Global Gene Therapy Market for Spinal Muscular Atrophy (SMA), 2018 - 2030 (USD Million)
Fig. 38 Global Spinal Muscular Atrophy (SMA) patients treated with gene therapy, 2018 - 2030
Fig. 39 Global Gene Therapy Market for Others, 2018 - 2030 (USD Million)
Fig. 40 Global Other diseases patient treated with gene therapy, 2018 - 2030
Fig. 41 Global Gene Therapy Market for Intravenous, 2018 - 2030 (USD Million)
Fig. 42 Global Gene Therapy Market for Others, 2018 - 2030 (USD Million)
Fig. 43 Regional Outlook, 2022 & 2030
Fig. 44 North America Gene Therapy Market 2018 - 2030 (USD Million)
Fig. 45 U.S. Gene Therapy Market 2018 - 2030 (USD Million)
Fig. 46 Canada Gene Therapy Market 2018 - 2030 (USD Million)
Fig. 47 Europe Gene Therapy Market 2018 - 2030 (USD Million)
Fig. 48 Germany Gene Therapy Market 2018 - 2030 (USD Million)
Fig. 49 UK Gene Therapy Market 2018 - 2030 (USD Million)
Fig. 50 France Gene Therapy Market 2018 - 2030 (USD Million)
Fig. 51 Italy Gene Therapy Market 2018 - 2030 (USD Million)
Fig. 52 Spain Gene Therapy Market 2018 - 2030 (USD Million)
Fig. 53 Asia Pacific Gene Therapy Market 2018 - 2030 (USD Million)
Fig. 54 Japan Gene Therapy Market 2018 - 2030 (USD Million)
Fig. 55 China Gene Therapy Market 2018 - 2030 (USD Million)
Fig. 56 Australia Gene Therapy Market 2018 - 2030 (USD Million)
Fig. 57 South Korea Gene Therapy Market 2018 - 2030 (USD Million)
Fig. 58 Rest of the world Gene Therapy Market 2018 - 2030 (USD Million)